Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

Overview of attention for article published in Lancet Oncology, January 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 3 news outlets
twitter: 24 X users
patent: 2 patents

f1000: 1 research highlight platform
guideline: 1 clinical guideline source

Readers on

mendeley: 373 Mendeley

So far, Altmetric has seen 25 X posts from 24 X users, with an upper bound of 150,313 followers.

@PestanaRC IPi/Nivo another option in UPS @NamBuiMD https://t.co/ThaP4D4rMN

https://t.co/eFWblJoXrx 작년 나온 논문. 연부조직육종에서 옵디보 단독 또는 옵디보 + 여보이 면역항암치료에 대한 2상 임상시험

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials https://t.co/gT0eRL18DN

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials" https://t.co/B6PVIPH6Nq

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 21 additional X posts.